Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.
Follow-Up Questions
Cynata Therapeutics Ltd 的 CEO 是誰？
Dr. Kilian Kelly 是 Cynata Therapeutics Ltd 的 Chief Executive Officer，自 2019 加入公司。
CYYNF 股票的價格表現如何？
CYYNF 的當前價格為 $0，在上個交易日 decreased 了 0%。
Cynata Therapeutics Ltd 的主要業務主題或行業是什麼？
Cynata Therapeutics Ltd 屬於 Biotechnology 行業，該板塊是 Health Care
